{
    "medicine_id": "43a4620788f59799d6cb9d030abca839b2a2d05c",
    "platform_id": "DB06040",
    "metadata": {
        "name": "Reagila 1 5 mg Capsule",
        "composition": "1 5 mg Filanesib",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in cancer tumors unspecified",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "This compound is a highly potent KSP inhibitor that demonstrates subnanomolar potency in both enzymatic and cellular assays and causes mitotic arrest leading to cell death or apoptosis of the immensely proliferating cancer cells",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Filanesib"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Filanesib"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Filanesib"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Filanesib"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}